Novel antibodies which have an impact on immune status after allogeneic hematopoietic cell transplantation.
Shigeo FujiAkihiro OhmotoPublished in: Expert review of hematology (2022)
While previous studies demonstrated a favorable prognosis in patients who received nivolumab prior to transplantation, the pretransplant use of nivolumab increases the incidence of GVHD, partly due to the expansion and activation of preexisting T cells. Mogamulizumab also has a significant impact on GVHD, caused by persistent depletion of regulatory T cells with CCR4 positivity. Regarding brentuximab vedotin, phase 1 trials have demonstrated considerable efficacy for steroid-refractory acute or chronic GVHD. In the future, sophisticated methods will be needed to determine the impact of each agent on immune status after allo-HCT.
Keyphrases
- regulatory t cells
- allogeneic hematopoietic stem cell transplantation
- dendritic cells
- hodgkin lymphoma
- stem cell transplantation
- bone marrow
- risk factors
- drug induced
- current status
- low dose
- respiratory failure
- stem cells
- acute lymphoblastic leukemia
- cell death
- acute myeloid leukemia
- cell therapy
- acute respiratory distress syndrome
- mechanical ventilation